Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 28;13(6):e70536.
doi: 10.1002/ccr3.70536. eCollection 2025 Jun.

Effective Treatment of Livedoid Vasculopathy With Oral Tofacitinib

Parvin Mansouri  1 , Nikoo Mozafari  2   3
Affiliations

Effective Treatment of Livedoid Vasculopathy With Oral Tofacitinib

Parvin Mansouri et al. Clin Case Rep. .

Abstract

We present a woman with severe refractory livedoid vasculopathy who was successfully treated with tofacitinib (5 mg twice a day). The ulcers gradually healed over a period of 2-3 months without experiencing any adverse events over a 1-year follow-up period. Tofacitinib may be considered a safe and effective therapy for patients with livedoid vasculopathy.

Keywords: JAK inhibitors; baricitinib; livedoid vasculopathy; tofacitinib.

PubMed Disclaimer

Conflict of interest statement

We declare that none of the authors listed on the manuscript are employed by a government agency that has a primary function other than research and/or education. None of the authors submitting this manuscript are acting as an official representative or on behalf of the government.The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
(a) Purpuric and punched‐out ulcerating lesions accompanied by atrophic scarring, telangiectasia, hemosiderin deposits, and hyperpigmentation over dorsum of feet and medial and lateral malleolus. (b) Two months after treatment, lesions completely healed with scarring.
See this image and copyright information in PMC

References

    1. Kerk N. and Goerge T., “Livedoid Vasculopathy – Current Aspects of Diagnosis and Treatment of Cutaneous Infarction,” Journal der Deutschen Dermatologischen Gesellschaft 11, no. 5 (2013): 407–410. - PubMed
    1. Vasudevan B., Neema S., and Verma R., “Livedoid Vasculopathy: A Review of Pathogenesis and Principles of Management,” Indian Journal of Dermatology, Venereology and Leprology 82, no. 5 (2016): 478–488. - PubMed
    1. Micieli R. and Alavi A., “Treatment for Livedoid Vasculopathy: A Systematic Review,” JAMA Dermatology 154, no. 2 (2018): 193–202. - PubMed
    1. Han Y. and Tu P., “Baricitinib Is Potentially Effective in the Treatment of Refractory Livedoid Vasculopathy,” Frontiers in Immunology 13 (2022): 1008392. - PMC - PubMed
    1. Jia E., Yan G., Xiao M., Geng H., Wei J., and Zhang J., “Refractory Ulcerations Associated With Livedoid Vasculopathy Successfully Treated With Tofacitinib,” Dermatologic Therapy 33, no. 6 (2020): e14470. - PMC - PubMed

LinkOut - more resources